Amarin vs. the Generics: Who Will Win?
My family's portfolios are filled with internet retailers that are skyrocketing, Software-as-a-Service stocks that are soaring, and one vaccine biotech that has jumped 2,000%. It's my first year writing for The Motley Fool, and simultaneously the best year of my 20-year investing career. But I've had some screw-ups, too.
In one article, I advocated that investors buy shares of Luckin Coffee. The next day the company said its revenue reports were fraudulent. But perhaps my biggest failure was with Amarin (NASDAQ: AMRN). I suggested on multiple occasions that investors might want to buy shares of the Irish biotech because of the company's amazing drug, Vascepa. In March a trial judge in Nevada invalidated several of the drug's patents. Amarin's stock dropped 70% overnight. Ouch.
Image source: Getty Images.
Source Fool.com
